{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:04:30Z","timestamp":1785351870044,"version":"3.55.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","immunology.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.iac.2017.01.009","type":"journal-article","created":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T07:50:06Z","timestamp":1490946606000},"page":"345-355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Biologic Therapy in Chronic Obstructive Pulmonary Disease"],"prefix":"10.1016","volume":"37","author":[{"given":"Julia W.","family":"Tripple","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"McCracken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Calhoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.iac.2017.01.009_bib1","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1164\/rccm.201204-0596PP","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary","volume":"187","author":"Vestbo","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.iac.2017.01.009_bib2","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S0140-6736(11)60990-2","article-title":"Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study","volume":"378","author":"Gershon","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.iac.2017.01.009_bib3","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1042\/CS20120340","article-title":"Phenotyping the heterogeneity of chronic obstructive pulmonary disease","volume":"124","author":"Barker","year":"2013","journal-title":"Clin Sci"},{"key":"10.1016\/j.iac.2017.01.009_bib4","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1172\/JCI36130","article-title":"The cytokine network in asthma and chronic obstructive pulmonary disease","volume":"118","author":"Barnes","year":"2008","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.iac.2017.01.009_bib5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nri2254","article-title":"Immunology of asthma and chronic obstructive pulmonary disease","volume":"8","author":"Barnes","year":"2008","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"10.1016\/j.iac.2017.01.009_bib6","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1136\/thoraxjnl-2014-206736","article-title":"Inflammasomes in COPD and neutrophilic asthma","volume":"70","author":"Kim","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.iac.2017.01.009_bib7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1177\/2040622315609251","article-title":"Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease","volume":"7","author":"George","year":"2016","journal-title":"Ther Adv Chronic Dis"},{"issue":"7","key":"10.1016\/j.iac.2017.01.009_bib8","doi-asserted-by":"publisher","first-page":"L619","DOI":"10.1152\/ajplung.00305.2014","article-title":"Increased IL-33 expression in chronic obstructive pulmonary disease","volume":"308","author":"Xia","year":"2015","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.iac.2017.01.009_bib9","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.it.2015.01.005","article-title":"Lung ILC2s link innate and adaptive responses in allergic inflammation","volume":"36","author":"Martinez-Gonzalez","year":"2015","journal-title":"Trends Immunol"},{"key":"10.1016\/j.iac.2017.01.009_bib10","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1164\/rccm.200404-511OC","article-title":"Tumor necrosis factor-\u03b1 drives 70% of cigarette smoke-induced emphysema in the mouse","volume":"170","author":"Churg","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.iac.2017.01.009_bib11","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1164\/rccm.200501-147OC","article-title":"First study of infliximab treatment in patients with chronic obstructive pulmonary disease","volume":"172","author":"Van Der Vaart","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.iac.2017.01.009_bib12","first-page":"146","article-title":"Comparison of inflammatory cytokines in chronic obstructive pulmonary disease, asthma and controls","volume":"7","author":"Keatings","year":"1997","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.iac.2017.01.009_bib13","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1164\/ajrccm.150.5.7952575","article-title":"Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease","volume":"150","author":"Di Francia","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.iac.2017.01.009_bib14","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1136\/thoraxjnl-2012-202432","article-title":"TNF\u03b1 antagonists for acute exacerbations of COPD: a randomised double-blind controlled trial","volume":"68","author":"Aaron","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.iac.2017.01.009_bib15","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.pupt.2007.03.003","article-title":"TNF-\u03b1 antagonists and the prevention of hospitalisation for chronic obstructive pulmonary disease","volume":"21","author":"Suissa","year":"2008","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.iac.2017.01.009_bib16","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1164\/rccm.200607-995OC","article-title":"The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease","volume":"175","author":"Rennard","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.iac.2017.01.009_bib17","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.rmed.2012.11.008","article-title":"Long-term safety study of infliximab in moderate-to-severe chronic obstructive pulmonary disease","volume":"107","author":"Rennard","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.iac.2017.01.009_bib18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.pupt.2015.01.005","article-title":"Canakinumab for the treatment of chronic obstructive pulmonary disease","volume":"31","author":"Rogliani","year":"2015","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.iac.2017.01.009_bib19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4161\/mabs.2.1.10328","article-title":"Canakinumab","volume":"2","author":"Dhimolea","year":"2010","journal-title":"MAbs"},{"key":"10.1016\/j.iac.2017.01.009_bib20","first-page":"A3964","article-title":"A phase 2 study of MEDI8968, an anti-interleukin-1 receptor I (IL-1RI) monoclonal antibody, in adults with moderate-to-very severe chronic obstructive pulmonary disease (COPD)","volume":"191","author":"Calverley","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.iac.2017.01.009_bib21","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1183\/09031936.00048509","article-title":"SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects","volume":"35","author":"Holz","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.iac.2017.01.009_bib22","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1164\/rccm.201405-0992OC","article-title":"CXCR2 antagonist MK-7123 a phase 2 proof-of-concept trial for chronic obstructive pulmonary disease","volume":"191","author":"Rennard","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.iac.2017.01.009_bib23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1159\/000334900","article-title":"IL-6 and IL-13 in induced sputum of COPD and asthma patients: correlation with respiratory tests","volume":"84","author":"Grubek-Jaworska","year":"2012","journal-title":"Respiration"},{"key":"10.1016\/j.iac.2017.01.009_bib24","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/j.1365-2249.2009.03965.x","article-title":"T\u00a0helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients","volume":"157","author":"Di Stefano","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.iac.2017.01.009_bib25","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1378\/chest.09-3058","article-title":"Expression of the T helper 17-associated cytokines IL-17A and IL-17F in asthma and COPD","volume":"138","author":"Doe","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.iac.2017.01.009_bib26","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1183\/09031936.00019207","article-title":"Interleukin-18 production and pulmonary function in COPD","volume":"31","author":"Imaoka","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.iac.2017.01.009_bib27","first-page":"39","article-title":"Eosinophilic airway inflammation in COPD","volume":"1","author":"Saha","year":"2006","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.iac.2017.01.009_bib28","first-page":"1995","article-title":"Airway eosinophilia in chronic bronchitis during exacerbations","volume":"1","author":"Saetta","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.iac.2017.01.009_bib29","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1164\/ajrccm.160.6.9811041","article-title":"Asthma attacks with eosinophilia predict mortality from chronic obstructive pulmonary disease in a general population sample","volume":"160","author":"Hospers","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.iac.2017.01.009_bib30","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1183\/09031936.00146306","article-title":"Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial","volume":"29","author":"Siva","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.iac.2017.01.009_bib31","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1164\/ajrccm.157.5.9709032","article-title":"Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease","volume":"157","author":"Seemungal","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.iac.2017.01.009_bib32","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1136\/thorax.57.10.847","article-title":"Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease","volume":"57","author":"Donaldson","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.iac.2017.01.009_bib33","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iac.2017.01.009_bib34","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.iac.2017.01.009_bib35","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iac.2017.01.009_bib36","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iac.2017.01.009_bib37","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.iac.2017.01.009_bib38","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.coi.2008.04.001","article-title":"IL-5 and eosinophilia","volume":"20","author":"Takatsu","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.iac.2017.01.009_bib39","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000330667","article-title":"Profiling of sputum inflammatory mediators in asthma and chronic obstructive pulmonary disease","volume":"83","author":"Bafadhel","year":"2012","journal-title":"Respiration"},{"key":"10.1016\/j.iac.2017.01.009_bib40","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1159\/000221902","article-title":"Sputum IL-5 concentration is associated with a sputum eosinophilia and attenuated by corticosteroid therapy in COPD","volume":"78","author":"Bafadhel","year":"2009","journal-title":"Respiration"},{"key":"10.1016\/j.iac.2017.01.009_bib41","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/S2213-2600(14)70187-0","article-title":"Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study","volume":"2","author":"Brightling","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.iac.2017.01.009_bib42","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1183\/09059180.00007609","article-title":"Investigational therapeutics targeting the IL-4\/IL-13\/STAT-6 pathway for the treatment of asthma","volume":"19","author":"Oh","year":"2010","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.iac.2017.01.009_bib43","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1172\/JCI10458","article-title":"Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema","volume":"106","author":"Zheng","year":"2000","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.iac.2017.01.009_bib44","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/j.1365-2249.2006.03167.x","article-title":"Intracellular cytokine profile of T lymphocytes in patients with chronic obstructive pulmonary disease","volume":"145","author":"Barcel\u00f3","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.iac.2017.01.009_bib45","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.cyto.2010.02.004","article-title":"Sputum biomarker profiles in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) and association between pulmonary function","volume":"50","author":"Eickmeier","year":"2010","journal-title":"Cytokine"},{"key":"10.1016\/j.iac.2017.01.009_bib46","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1398-9995.2008.01717.x","article-title":"Induced sputum and bronchial mucosal expression of interleukin-13 is not increased in chronic obstructive pulmonary disease","volume":"63","author":"Saha","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.iac.2017.01.009_bib47","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/j.jaci.2006.02.013","article-title":"Cytokine production by bronchoalveolar lavage T lymphocytes in chronic obstructive pulmonary disease","volume":"117","author":"Barczyk","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2017.01.009_bib48","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1378\/chest.07-2626","article-title":"Tc2 response at the onset of COPD exacerbations","volume":"134","author":"Makris","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.iac.2017.01.009_bib49","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.rmed.2004.10.005","article-title":"Changes in sputum T-lymphocyte subpopulations at the onset of severe exacerbations of chronic obstructive pulmonary disease","volume":"99","author":"Tsoumakidou","year":"2005","journal-title":"Respir Med"},{"key":"10.1016\/j.iac.2017.01.009_bib50","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jaci.2013.03.051","article-title":"Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids","volume":"132","author":"Noonan","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2017.01.009_bib51","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1183\/09031936.00223411","article-title":"A\u00a0phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma","volume":"41","author":"Piper","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.iac.2017.01.009_bib52","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jaci.2012.03.030","article-title":"IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor \u03b1 antagonist","volume":"130","author":"Slager","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2017.01.009_bib53","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N\u00a0Engl J Med"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856117300097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856117300097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T22:56:32Z","timestamp":1535928992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856117300097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0889856117300097"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2017.01.009","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologic Therapy in Chronic Obstructive Pulmonary Disease","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2017.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}